Last year JDRF took a number of significant actions to broaden the resources available in the T1D research and development space – three of them are highlighted here. Each of these will help speed progress towards our research goals across our portfolio of research objectives to develop and deliver novel T1D therapies to patients. In […]
A clinical study published in PNAS provides further proof-of-concept that beta cell encapsulation holds real promise for making islet implantation a viable therapy for people with type 1 diabetes (T1D).
Type 1 diabetes (T1D) scientists have believed for some time that communities of bacterial microorganisms in the gut, which make up the microbiome, are in some way related to immune system defects and the autoimmune response that leads to T1D. Previous research has hypothesized that the diversity or abundance of specific bacteria within the microbiome […]
Last September, results from a JDRF-funded study were announced by Sansum Diabetes Research Institute and JDRF. This study addresses one of the key limitations of early artificial pancreas systems – the challenge of mealtime dosing of insulin. This is because insulin delivered through the skin by a pump or injections works much slower than insulin […]
Last September, Medtronic announced FDA approval of its MiniMed 530G with Enlite system (sold outside the United States as the Veo since 2009). JDRF applauded the U.S. Food and Drug Administration (FDA) for its commitment to ensuring patients in the United States can access insulin pumps that can temporarily stop insulin delivery once sensor glucose […]
JDRF and Ford Customer Service Division (FCSD) joined forces to help raise awareness and funds for type 1 diabetes (T1D) research through the “Our Everyday Heroes” Race Car Design Contest for JDRF. The winning design was painted onto the Motorcraft/Quick Lane Ford Shelby Mustang Funny Car driven by Bob Tasca III. The contest has raised […]